Analysis of fexofenadine in pharmaceutical formulations using tris(1,10‐phenanthroline)–ruthenium(II) peroxydisulphate chemiluminescence system in a multichip device | Zendy

Al Lawati Haider A. J. | Zendy; Al Dahmani Zeiyana M. | Zendy; Suliman Fakhr Eldin O. | Zendy; Al Kindy Salma M. Z. | Zendy; AlLawati Ali M. | Zendy

Premium

Analysis of fexofenadine in pharmaceutical formulations using tris(1,10‐phenanthroline)–ruthenium(II) peroxydisulphate chemiluminescence system in a multichip device

Author(s) -

Al Lawati Haider A. J.,

Al Dahmani Zeiyana M.,

Suliman Fakhr Eldin O.,

Al Kindy Salma M. Z.,

AlLawati Ali M.

Publication year - 2011

Publication title -

luminescence

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.428

H-Index - 45

eISSN - 1522-7243

pISSN - 1522-7235

DOI - 10.1002/bio.1310

Subject(s) - chemiluminescence , ruthenium , phenanthroline , fexofenadine , tris , chemistry , combinatorial chemistry , nuclear chemistry , photochemistry , chromatography , organic chemistry , pharmacology , medicine , catalysis , biochemistry

A simple, rapid and sensitive method has been developed for the analysis of fexofenadine (FEX) in pharmaceutical formulations, using a tris(1,10‐phenanthroline)–ruthenium(II) [Ru(phen) 3 2+ ] peroxydisulphate chemiluminescence (CL) system in a multichip device. Various parameters that influence the CL signal intensity were optimized. These included pH, flow rates and concentration of reagents used. Under optimum conditions, a linear calibration curve in the range 0.05–5.0 µg/mL was obtained. The detection limit was found to be 0.001 µg/mL. The procedure was applied to the analysis of FEX in pharmaceutical products and was found to be free from interference from concomitants usually present in these preparations. Copyright © 2011 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research